Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trialResearch in context

Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trialResearch in context

Summary: Background: Some locally advanced (IIIA/IIIB) non-small cell lung cancers (NSCLCs) might have surgical options available. However, information regarding the effectiveness of neoadjuvant immunotherapy for potentially resectable IIIA/IIIB NSCLC is limited. The intent of this investigation wa...

Full description

Bibliographic Details
Main Authors: Chao Sun, Xu Wang, Yinghui Xu, Guoguang Shao, Xi Chen, Yunpeng Liu, Peng Zhang, Xingyu Lin, Xiaobo Ma, Shi Qiu, Hua He, Zhiguang Yang, Kewei Ma
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:EClinicalMedicine
Subjects:
Non-small cell lung cancer
Potentially resectable
Locally advanced
Neoadjuvant
Chemoimmunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024000014

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024000014

Similar Items